

References

1. Ananthkrishnan, A.N., Khalili, H. and Giannini, H., 2017. A study of the association between butyrate-producing bacteria and clinical responses to biologic therapy in patients with inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 46(7), pp.659-668.
2. Andoh, A., Zhang, Z., and Mitsuyama, K., 2012. Changes in the gut microbiota in patients with inflammatory bowel disease. *Journal of Clinical Gastroenterology*, 46(8), pp.733-738.
3. Bamola, D.V., et al., 2021. Probiotics in the management of inflammatory bowel disease: a randomized controlled trial. *Gut Microbes*, 12(1), pp.1-14.
4. Bernstein, C.N., et al., 2003. The incidence of extraintestinal manifestations in inflammatory bowel disease. *American Journal of Gastroenterology*, 98(4), pp.979-986.
5. British Dietetic Association (BDA) (2020). *Probiotics: What are they and do they work?* Available at: <https://www.bda.uk.com/resource/probiotics.html> (Accessed: 21 October 2024).
6. British Society of Gastroenterology (BSG) (2019). *Guidelines on the use of probiotics in the management of gastrointestinal disorders*. Available at: <https://www.bsg.org.uk/clinical-practice/guidelines/probiotics-in-the-management-of-gastrointestinal-disorders/> (Accessed: 21 October 2024).
7. Camilleri, M., et al., 2015. Diarrhoea and irritable bowel syndrome: review of clinical features and treatment. *Alimentary Pharmacology & Therapeutics*, 42(8), pp.934-948.
8. Chen, M., et al., 2021. Probiotics for the management of inflammatory bowel disease: a systematic review and meta-analysis. *European Journal of Gastroenterology & Hepatology*, 33(8), pp.1045-1051.
9. Estevinho, M., et al., 2024. Efficacy of probiotics in maintaining remission in inflammatory bowel disease: a systematic review. *World Journal of Gastroenterology*, 30(2), pp.142-156.
10. Farmer, A.D., et al., 2013. Bloating: prevalence and association with quality of life in the community. *BMC Gastroenterology*, 13(1), pp.1-7.
11. Ford, A.C., et al., 2009. Inflammatory bowel disease and irritable bowel syndrome: common manifestations and differences. *Alimentary Pharmacology & Therapeutics*, 29(10), pp.1109-1120.
12. Ford, A.C., et al., 2020. The overlap between irritable bowel syndrome and inflammatory bowel disease: a clinical dilemma. *The Lancet Gastroenterology & Hepatology*, 5(3), pp.203-209.
13. Ford, A.C. (2020). 'Overlap between irritable bowel syndrome and inflammatory bowel disease', *Gastroenterology & Hepatology (New York)*, 16(4), pp. 211-213.
14. Ghelani, H., et al., 2023. Inflammatory bowel disease: pathophysiology, diagnosis, and treatment. *The British Journal of Surgery*, 110(2), pp.102-113.

15. Glassner, K.L., et al., 2020. The microbiome and inflammatory bowel disease. *J Allergy Clin Immunol*, 145(1)pp.16-27.
16. Gracie, D.J., et al. (2017). 'The prevalence of irritable bowel syndrome in patients with inflammatory bowel disease: a cross-sectional study', *Alimentary Pharmacology & Therapeutics*, 46(5), pp. 454-462.
17. Guan, Q., 2019. Inflammatory bowel disease: from pathogenesis to therapy. *World Journal of Gastroenterology*, 25(6), pp.1024-1036.
18. Guslandi, M., Mezzi, G., Sorghi, M. & Testoni, P.A. (2003). *Saccharomyces boulardii* in maintenance treatment of Crohn's disease. *Digestive Diseases and Sciences*, 48(4), pp. 742-745.
19. Han, S., Wang, Y., Yao, Z., Ren, X., Wang, X., Ma, L., Zhang, H. & Gong, Z. (2022). Role of gut microbiota in pathogenesis and management of inflammatory bowel disease. *World Journal of Gastroenterology*, 28(19), pp. 2058-2081.
20. Hedin, C.R., Cox, E., Rondon, M.R., Virta, L., Myrelid, P., Parkes, M. & Lindsay, J.O. (2017). Early fecal microbiota transplantation for severe acute refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. *The Lancet Gastroenterology & Hepatology*, 2(1), pp. 1-11.
21. Henriksen, M., et al. (2018). 'The prevalence of irritable bowel syndrome in patients with ulcerative colitis: an observational study', *Scandinavian Journal of Gastroenterology*, 53(1), pp. 19-25.
22. Huang, C., Liu, Y., and Jiang, H. (2023). Gut microbiota dysbiosis in irritable bowel syndrome: A meta-analysis of 16S rRNA sequencing studies. *Journal of Translational Medicine*, 21(1), 124.
23. IBS Network (2022). *Probiotics and IBS: What you need to know*. Available at: <https://www.ibsnetwork.org/probiotics-and-ibs/> (Accessed: 21 October 2024).
24. Joossens, M., et al., 2011. A decrease in the diversity of the gut microbiota of patients with Crohn's disease. *Gastroenterology*, 141(1), pp.116-121.
25. Ke H, Li Z, Lin Q, Shen Z, Chen Y and Chen J (2023). Inflammatory bowel disease is causally related to irritable bowel syndrome: a bidirectional two-sample Mendelian randomization study. *Front. Med.* 10:1166683.
26. Keeley, M.F., et al., 2020. The association of inflammatory bowel disease with irritable bowel syndrome: a systematic review and meta-analysis. *Alimentary Pharmacology & Therapeutics*, 52(5), pp.783-796.
27. Keeley, M.F., Fairbrass, K., et al. (2020). 'The prevalence of irritable bowel syndrome symptoms in patients with inflammatory bowel disease: a meta-analysis', *BMC Gastroenterology*, 20(1), p. 211.
28. Kolho, K.L., et al., 2015. The role of the gut microbiome in inflammatory bowel disease. *Current Opinion in Gastroenterology*, 31(4), pp.368-373.
29. Lacy, B.E., et al., 2016. Diarrhea-predominant irritable bowel syndrome: diagnosis and management. *American Family Physician*, 93(3), pp.219-226.

30. Lahermes, A., Gendron, F., and Launay, J.M. (2018). E. coli infection mimics quiescent inflammatory bowel disease in a mouse model with IBS-like symptoms. *BMC Microbiology*, 18(1), pp. 54.
31. Landers, C.J., et al., 2002. Anti-Escherichia coli antibodies in Crohn's disease. *Journal of Clinical Gastroenterology*, 34(4), pp.350-353.
32. Lee, J., et al., 2022. Probiotics for the management of IBS-like symptoms in ulcerative colitis patients. *Digestive Diseases and Sciences*, 67(8), pp.2345-2354.
33. Lembo, A., et al., 2015. Symptoms and quality of life in patients with irritable bowel syndrome and inflammatory bowel disease. *Gastroenterology*, 149(4), pp.911-918.
34. Lomer, M.C.E., Stagg, A.J., and Sanders, D.S. (2022). British Dietetic Association evidence-based guidelines for the dietary management of adults with inflammatory bowel disease. *Journal of Human Nutrition and Dietetics*, 35(1), pp. 13-24.
35. Lyra, A., Krogus-Kurikka, L., Nikkilä, J., Malinen, E., Kajander, K., Kurikka, K., Korpela, R. & Palva, A. (2016). Effect of Lactobacillus acidophilus NCFM on abdominal pain and bloating in patients with irritable bowel syndrome: A randomized, double-blind, placebo-controlled study. *Clinical Nutrition*, 35(1), pp. 11-17.
36. Mahler, A., et al., 2010. Calprotectin in inflammatory bowel disease: the role of antibodies and fecal calprotectin levels. *Alimentary Pharmacology & Therapeutics*, 32(5), pp.709-716.
37. McFarland, L.V., Evans, C.T. & Goldstein, E.J.C. (2018). Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. *Frontiers in Medicine*, 5, 124.
38. McFarland, L.V., Evans, C.T. & Goldstein, E.J.C. (2021). Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. *Frontiers in Medicine*, 8, 670465.
39. Mei, Q., Xue, Y., and Li, T. (2021). Altered gut microbiota in patients with inflammatory bowel disease: A systematic review and meta-analysis. *Frontiers in Microbiology*, 12, 737710.
40. Mei, L., Zhou, J., Su, Y., Mao, K., Wu, J., Zhu, C., He, L. & Cui, Y., 2021. Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome. *BMC Gastroenterology*, 21(1), p.105.
41. Metwaly, A., et al., 2020. Bacterial metabolite interactions and their implications for Crohn's disease. *Nature Microbiology*, 5(3), pp.397-409.
42. Mingshi, C., Zhang, Z., Liu, Y., Wang, H., and Zhang, Y. (2021). The effects of probiotics on the maintenance of remission in inflammatory bowel disease: A systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, 19(4), pp. 855-867.
43. Mitsuyama, K., Niwa, M., Takedatsu, H., Yamasaki, H., Kuwaki, K., Yoshioka, S., Yamauchi, R., Fukunaga, S. and Torimura, T. (2016). 'Antibody markers in the diagnosis of inflammatory bowel disease', *World Journal of Gastroenterology*, 22(3), pp. 1304-1310.

44. National Health Service (NHS) (2021). *Irritable bowel syndrome (IBS) treatment*. Available at: <https://www.nhs.uk/conditions/irritable-bowel-syndrome-ibs/treatment/> (Accessed: 21 October 2024).
45. Ng, S.C., Plamondon, S., Kamm, M.A., Hart, A.L., Al-Hassi, H.O., Guenther, T., Stagg, A.J. & Knight, S.C., 2010. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. *Inflammatory Bowel Diseases*, 16(8), pp.1286-1298.
46. Ohlsson, B., et al., 2022. Long-term complications in inflammatory bowel disease: a clinical perspective. *International Journal of Colorectal Disease*, 37(3), pp.709-718.
47. Ohman, L., et al., 2015. The role of the immune system in irritable bowel syndrome and inflammatory bowel disease. *Gut*, 64(1), pp.104-114.
48. Ott, S.J., Musfeldt, M., Wenderoth, D.F., et al. (2004). 'Reduction of diversity of the colonic mucosa in ulcerative colitis', *The American Journal of Gastroenterology*, 99(9), pp. 1770-1775.
49. Pang, J. X. Q., Kheirkhahrahimabadi, H., Bindra, S., Bindra, G., Panaccione, R., Eksteen, B., et al. (2021). Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis in a Canadian cohort. *J. Can. Assoc. Gastroenterol.* 4, 65–72.
50. Piche, T., et al., 2010. Abdominal pain in irritable bowel syndrome: clinical features and the role of psychosocial factors. *Alimentary Pharmacology & Therapeutics*, 32(1), pp.25-32.
51. Phan, J., Das, R., and Chen, S. (2021). Understanding the role of gut microbiota in irritable bowel syndrome: Current insights. *Frontiers in Microbiology*, 12, 666091.
52. Porter, C., et al., 2012. Incidence of inflammatory bowel disease in patients with irritable bowel syndrome: a large observational study. *Journal of Gastroenterology and Hepatology*, 27(1), pp.90-94.
53. Porter, C., Hsu, H., and McGowan, L. (2012). The relationship between inflammatory bowel disease and irritable bowel syndrome: A clinical perspective. *Journal of Clinical Gastroenterology*, 46(9), pp. 746-753
54. Rao, S.S.C., et al., 2000. Urgency to defecate in patients with irritable bowel syndrome: clinical correlates and impact on quality of life. *American Journal of Gastroenterology*, 95(8), pp.2136-2142.
55. Ramos, G.P., et al., 2019. Dysbiosis in inflammatory bowel disease: a new perspective on the gut microbiome. *World Journal of Gastroenterology*, 25(11), pp.1290-1301.
56. Riba, A., Rios, J., and Karner, J. (2017). Increased gut permeability and visceral hypersensitivity are linked to higher E. coli levels in mice. *Neurogastroenterology & Motility*, 29(4), e13032.
57. Ringel, Y., et al., 2011. Lactobacillus acidophilus NCFM® for the management of IBS: a randomized controlled trial. *Alimentary Pharmacology & Therapeutics*, 34(2), pp.155-163.

58. Rodemann, M., Franke, A., et al. (2007). 'Pathogenicity of Escherichia coli in patients with inflammatory bowel disease', *Inflammatory Bowel Diseases*, 13(9), pp. 1175-1182.
59. Rome Foundation, 2024. *Rome IV Criteria*. Available at: <https://theromefoundation.org/rome-iv/rome-iv-criteria/> [Accessed 23 October 2024].
60. Ryan, F.J., O'Sullivan, O., and O'Neill, B. (2020). Gut microbiome dysbiosis in patients with irritable bowel syndrome: A systematic review. *Gastroenterology*, 158(6), pp. 1568-1580.
61. Sood, A., Midha, V., Makharia, G.K., Ahuja, V., Singal, D., Goswami, P. & Tandon, R.K., 2009. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clinical Gastroenterology and Hepatology*, 7(11), pp.1202-1209
62. Spiller, R., et al., 2000. Inflammation in the gastrointestinal tract and its relation to irritable bowel syndrome. *Alimentary Pharmacology & Therapeutics*, 14(2), pp.181-187.
63. Sultan S et al., 2021. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. *Front. Physiol. Volume 12*: <https://doi.org/10.3389/fphys.2021.715506>
64. Tursi, A., Brandimarte, G., Giorgetti, G.M., Elisei, W., Maiorano, M. & Aiello, F. (2010). Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone in the treatment of acute mild-to-moderate ulcerative colitis. *Medical Science Monitor*, 16(10), pp. CR405-CR412.
65. Via, M.A., De Marco, D., and Zorzetto, F. (2018). Dysbiosis and gut microbiota diversity in inflammatory bowel disease: A systematic review. *BMC Gastroenterology*, 18(1), pp. 109.
66. Vavricka, S.R., et al., 2015. Extraintestinal manifestations in inflammatory bowel disease: a review. *European Journal of Internal Medicine*, 26(4), pp.203-207.
67. Waller, P.A., et al., 2011. The effect of Bifidobacterium lactis HN019 on digestive symptoms in a controlled trial. *Journal of Clinical Gastroenterology*, 45(3), pp.238-243.
68. Wang, L., Liu, Z., and Zhang, H. (2020). Microbial metabolites and the gut-brain axis in irritable bowel syndrome. *Frontiers in Neuroscience*, 14, 154.
69. Won Moon, C.M., Park, S.J., Kim, E.S., Kim, T.I., Kim, W.H. & Cheon, J.H. (2020). Retrospective study of Saccharomyces boulardii in patients with Crohn's Disease: Efficacy in reducing Crohn's Disease Activity Index. *Digestive Diseases and Sciences*, 65(2), pp. 567-577.
70. World Gastroenterology Organisation (WGO) (2020). *Gut microbiota and probiotics in health and disease*. Available at: <https://www.wgo.org/global-guidelines/gut-microbiota-and-probiotics-in-health-and-disease> (Accessed: 21 October 2024).
71. Wu Y, Li Y, Zheng Q, Li L. The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. *Nutrients*. 2024; 16(13):2114.
72. Xie, P., Zhang, Z., Wang, J., He, X., Liu, Y., Zhang, G. (2023). Clinical efficacy of probiotics in patients with irritable bowel syndrome: A meta-analysis of randomized controlled

trials. *Journal of Clinical Gastroenterology*, 57(4), pp. 363-372. Zhang, T., Li, Q., Cheng, L., Li, C. & Liu, H. (2022). Advances in the effects of probiotics on intestinal flora and inflammatory bowel diseases. *Frontiers in Immunology*, 13, 807306.

73. Yamada, E., Hara, Y., and Matsumoto, M. (2014). A review of the relationships between inflammatory bowel disease and irritable bowel syndrome: Are they related? *World Journal of Gastroenterology*, 20(10), pp. 2672-2681.
74. Yamada, E., Hara, Y., and Matsumoto, M. (2014). A review of the relationships between inflammatory bowel disease and irritable bowel syndrome: Are they related? *World Journal of Gastroenterology*, 20(10), pp. 2672-2681.
75. Yang, R., Chen, H., Zhang, Y., Wang, C. (2024). Probiotics and the treatment of irritable bowel syndrome: A comprehensive meta-analysis. *World Journal of Gastroenterology*, 30(5), pp. 715-728.
76. Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X. and Li, Y. (2016). Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. *BMC Gastroenterology*, 16(1), 62.
77. Zhuang, X., Zhang, Y., and Liu, W. (2018). The gut microbiota and irritable bowel syndrome: A review. *Journal of Gastroenterology and Hepatology*, 33(5), pp. 1104-1110.